ATHE
Alterity Therapeutics Ltd.
NASDAQ · Healthcare · Biotechnology · AU
$2.43
−7.25%Oct 5, 2026, 11:05 UTC
Alterity Therapeutics presented new analyses of ATH434 Phase 2 data in multiple system atrophy at the 2026 International Congress of Parkinson's Disease and Movement Disorders, reporting that ATH434 50 mg slowed functional decline by approximately 52% versus placebo on the 11-item UMSARS at Week 52 with CSF NfL as a covariate.
Source:Aug 12, 2026, 11:05 UTC
Alterity Therapeutics announced the granting of a new U.S. composition of matter patent for its drug candidate ATH434, extending protection to at least 2045.
Source:Jul 7, 2026, 11:05 UTC
Alterity Therapeutics received FDA End-of-Phase 2 meeting minutes confirming the registrational pathway for ATH434 in Multiple System Atrophy.
Jun 9, 2026, 11:05 UTC
Alterity Therapeutics achieved alignment with the U.S. FDA on the pivotal Phase 3 program for ATH434 in Multiple System Atrophy.